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THE DEVELOPMENT OF A MOUSE MODEL OF POST-BARIATRIC 
HYPERINSULINEMIC HYPOGLYCEMIA 
CATHERINE M. SMITH 
ABSTRACT 
Background Post-bariatric hypoglycemia (PBH), a complication of gastric bypass 
surgery, is characterized by postprandial hyperinsulinemic hypoglycemia. To date, the 
etiology of PBH has not been fully elucidated. 
Objective To develop a murine model of PBH by experimentally modifying candidate 
molecules identified in humans with PBH. 
Methods Gastric bypass patients were assigned to groups based on whether or not they 
suffered from hypoglycemia (PBH, n = 11; asymptomatic, n = 7). Patients underwent a 
mixed meal tolerance test with blood draws at baseline, 30 minutes, and 120 minutes 
postprandially. SOMAscan (Somalogic) was used to evaluate serum for protein levels. In 
parallel, mass spectrometry (Metabolon) was used to examine metabolite levels. Mice 
were treated with the Farnesoid X Receptor (FXR) agonist, fexaramine (Fex), or vehicle 
for 5 days before undergoing a glucose tolerance test (GTT). Mice were sacrificed with 
tissues collected immediately thereafter. PCR was performed to quantify expression of 
FXR target genes. A separate cohort of mice was treated with adenine or vehicle for 2 
days before undergoing a GTT or an insulin tolerance test.  
Results FGF19 was the most significantly upregulated protein in the PBH group at all 
time points. At 120 minutes postprandially, FGF19 was 2.1-fold higher in the PBH group 
(p < 1x10-5). Adenine was >2-fold higher at all time points (p < 1x10-8).  Treatment with 
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Fex did not result in significant differences during GTT or in expression of FXR target 
genes. Treatment with adenine did not significantly impact glucose tolerance or insulin 
sensitivity between groups. 
Conclusions The results of the human serum analyses established a strong foundation on 
which to develop a murine model of PBH. Though the mouse experiments failed to 
induce postprandial hypoglycemia, they have directed future experiments toward 
developing a murine model of PBH.  
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INTRODUCTION 
 
The Role of Gastric Bypass Procedures in Combating the Obesity Epidemic 
The prevalence of obesity in the United States population has reached epidemic 
levels with 35.7% of adults being characterized as obese (body mass index (BMI) = 30 – 
39.9) and an additional 6.3% of the adult population being characterized as severely 
obese (BMI ≥ 40) as of 20101. Obesity is a key risk factor for Type 2 Diabetes Mellitus 
(T2DM), cardiovascular diseases, and significantly increases the likelihood of mortality. 
Medical treatments utilizing lifestyle changes and pharmaceuticals targeting obesity have 
failed to yield sustainable weight loss. Randomized clinical trials have shown that gastric 
bypass procedures are more likely to result in prolonged weight reduction than the best 
medical treatment available (28.4 – 31.1% versus 6.9% reduction in weight)2. In addition, 
gastric bypass patients also experience resolution of many other obesity-associated 
comorbidities compared with patients receiving only medical intervention 2. 
Among these resolutions of comorbidities associated with gastric bypass is acute 
and sustained remission of T2DM, as defined by hemoglobin A1C (HbA1C) levels and 
fasting serum glucose levels2. Resolution of a patient’s previously diagnosed T2DM can 
be seen within days postoperatively, preceding any substantial reduction in body mass3. 
This rapid resolution of T2DM following gastric bypass surgery is well documented in 
the literature; however, the mechanisms leading to this correction remain to be 
elucidated2-4. The Swedish Obese Subjects (SOS) study, a longitudinal observational 
study that began in 1987, confirmed that gastric bypass procedures were linked to a lower 
	2	
risk of mortality and the afore-mentioned comorbidities as compared to medical 
treatment. Two years postoperatively, 72% of patients with preoperative T2DM were in 
remission. Gastric bypass procedures also reduced the incidence of T2DM in patients 
without the disease preoperatively by at least 80%3. Randomized clinical trials, ranging 
from 1 year to 3 years, have shown that patients receiving RYGB have greater remission 
of T2DM (defined by HbA1C < 6.0 – 6.5%, depending on study) than patients receiving 
only medical therapy. This greater rate of remission was seen at both one year and three 
years postoperatively5,6. Postoperative patients also show a greater reduction in body 
mass and improved quality of life measures at both one year and three years 
postoperatively than medical therapy patients5,6. 
RYGB is now the most common bariatric procedure performed, accounting for 
70% of the bariatric procedures performed worldwide7. RYGB has been linked to more 
effective weight loss as well as more immediate and prolonged resolution of 
comorbidities associated with obesity than other bariatric procedures, including 
laparoscopic gastric band (LAGB) and laparoscopic sleeve gastrectomy (LSG)5,7. 
The altered anatomy of the digestive tract, as a result of the RYGB procedure, has 
several implications on physiology. The RYGB procedure involves suturing the stomach 
to create a small gastric pouch8. The pouch is connected to the jejunal portion of the 
small intestine; thus allowing food to bypass the duodenum. This “bypass” of the initial 
portion of the small intestine accounts for the malabsorptive aspects of the surgery as 
fewer nutrients are absorbed. The variable length of the limb may impact the degree of 
malabsorption8. The bypassed portion of the stomach remains in the peritoneal cavity, 
	3	
attached to the duodenum, and thus secretions from the remnant stomach as well as bile 
and exocrine pancreatic secretions are still received by the small intestine. 
 
Post-Surgical Complications of Roux-en-Y Gastric Bypass Surgery 
As with any operative procedure, RYGB has been associated with a variety of 
adverse postoperative complications. Immediate complications following RYGB 
procedures may include staple line leak, postoperative hemorrhage, and bowel 
obstructions9. Subsequent complications may include weight gain, which occurs in 10% 
of patients after 5 years and 20% of patients after 10 years, as well as nutritional 
deficiencies, anastomoses in the gastrojejunal regions, and other complications10. 
A lesser-known complication manifesting approximately 1 - 3 years 
postoperatively is post-bariatric hypoglycemia (PBH). This condition involves 
debilitating hyperinsulinemic hypoglycemia, which may present with or without 
neuroglycopenia11. Though much remains to be uncovered about the etiology of this 
adverse postoperative complication, it is known that symptoms manifest gradually and 
worsen over time11. The severity of the hypoglycemic response appears to increase after 
ingestion of high glycemic index carbohydrates11,12. Diagnosis can be confirmed by 
measuring a patient’s blood glucose postprandially. Blood glucose will rise rapidly and 
peak. As glucose is cleared, serum glucose reaches an atypical glucose nadir below 70 
mg/dL. This occurs roughly 1 - 3 hours postprandially. PBH patients exhibit abnormally 
high blood insulin levels at the time of hypoglycemia (hyperinsulinemic hypoglycemia), 
despite low serum glucose levels11.  
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A better understanding of the dysregulation of glycemic control in PBH patients 
has been obtained via use of a Continuous Glucose Monitor (CGM). A 24-hour reading 
from a PBH patient can be seen in Figure 1, below, and is typical for a patient suffering 
from PBH. Patients will maintain normal serum glucose levels while fasting with 
hypoglycemic events occurring only during postprandial periods. The onset of the 
postprandial hypoglycemia varies, but typically occurs 1 – 3 hours after eating.  Patients 
may treat hypoglycemia by eating or taking glucose tablets. Recombinant glucagon 
(GCG) is also available for use during a hypoglycemic event, but the current GCG 
treatment does not facilitate use in case of emergency. Several other medical therapies 
targeted at combating hypoglycemic episodes exist including acarbose, octreotide, among 
others11.  
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Figure 1: Continuous Glucose Monitor output from PBH patient seen at Joslin 
Diabetes Center Over the course of 24 hours (on x-axis) repeated hypoglycemic 
episodes can be seen postprandially. Between 12 AM and approximately 9:30 AM, while 
the patient sleeps, no hypoglycemic event is recorded. PBH patients do not typically 
suffer from fasting hypoglycemia, as hypoglycemic episodes are typically associated with 
the oral intake of food. After the patient eats (indicated by purple arrow) glucose rises 
rapidly. Roughly 2 – 2.5 hours after the meal, a hypoglycemic event (indicated by red 
arrow) occurs where the glucose nadir reaches a subnormal level (here defined as below 
the threshold of 70 mg/dL). Patients may attempt eating again to increase glucose levels, 
but may experience subsequent hypoglycemic events in response to oral intake of food 
(as seen above after second purple meal arrow).  Source: Suhl, E, et al. Surgery for 
Obesity and Related Diseases 2017. 
 
The severity and prevalence of PBH amongst post-bariatric patients varies 
depending on the methodology used to ascertain presence of symptoms. Roughly 0.2-1% 
of post-RYGB patients are hospitalized as a result of a severe hypoglycemic episode with 
another 0.4-7.6% diagnosed in clinic with symptoms of PBH14. However, the percentage 
of patients suffering from symptoms of PBH may be higher than documented due to 
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under-diagnoses and lack of awareness of the complication13,14. Self-reports of presence 
of symptoms of PBH reveal higher rates of hypoglycemic symptoms. As many as 38% of 
post-gastric bypass patients indicated mild to moderate postprandial hypoglycemic 
symptoms when surveyed13,14..  
 
Characteristics of Patients Suffering from Post-Bariatric Hypoglycemia 
Much remains unknown regarding the etiology and pathogenesis of PBH, but 
genetic variations, anatomical alterations, as well as hormonal and microbiome changes 
associated with bariatric surgery likely contribute to the development of the 
syndrome11,15. Figure 2, below, expands upon the physiological mechanisms that may 
contribute to the development of PBH.  
Decreased transit time from stomach to small intestine results in a large spike in 
blood glucose levels beyond the normal postprandial range11,12. Though blood glucose 
reaches a higher peak, it will subsequently be followed by a lower nadir, often leading to 
symptoms of neuroglycopenia. A noteworthy observation is that patients’ serum insulin 
levels are inappropriately high at the time of the hypoglycemic event. Patients do not 
experience hypoglycemia while fasting, indicating that hypoglycemic events are 
associated with oral intake of food. The pathophysiology of PBH seems to be linked to an 
inappropriate β-cell response to oral stimuli12. The hypoglycemic events that occur in 
response to oral stimuli are not seen in response to intravenous administration of 
glucose12. This information suggests that the altered anatomy of the GI system in post-
RYGB patients contributes to PBH patients’ hypoglycemic events.   
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Figure 2: Alterations in anatomical structure of the gastrointestinal tract following 
RYGB surgery leads to altered physiology A combination of mechanisms are believed 
to act in concert resulting in postprandial hypoglycemic episodes. Hypoglycemia directly 
results from increased circulating insulin. Serum insulin is abnormally high at the time of 
hypoglycemia as a result of increased incretin secretion, increased sensitivity of 
pancreatic β- cells to glucose, among other mechanisms. Non-insulin dependent 
mechanisms are also believed to impact glucose disposal, and further decrease serum 
glucose levels to a lower nadir. Source: Patti, ME, Goldfine, AB Gastroenterology 2014. 
 
Further hypothesized mechanisms contributing to PBH patients’ postprandial 
hypoglycemia include increased circulating incretin levels, such as glucagon-like peptide-
1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP)16, dysregulation of islet function16, 
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alterations in bile acid pool composition, as well as alterations in gut microflora13. 
Increased insulin secretion is a result of glucose-dependent mechanisms, with possible 
contributions from glucose-independent mechanisms16,17. Nevertheless, factors beyond 
insulin secretion should be considered. Patients’ postprandial hypoglycemia is believed to 
result from an undetermined interplay of insulin-dependent as well as insulin-independent 
mechanisms.  
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SPECIFIC AIMS  
 We hypothesize that there are quantifiable differences in protein abundance 
and/or serum levels of metabolites that contribute to PBH. This study aims to first 
identify proteins and metabolites differentially expressed in patients with PBH using 
independent proteomic and metabolomics assays. Candidate molecules with glycemic 
implications will be tested in a mouse model by increasing their expression and testing 
for postprandial hypoglycemia. This study aims to ultimately develop a mouse model of 
PBH.  
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METHODS 
 
Study Population and Patient Characteristics 
The Joslin Diabetes Center Institutional Review Board approved this study. 
Informed consent was obtained for each patient. Patients were divided into four groups 
based upon the following parameters: patients having undergone RYGB who presented 
with symptoms of PBH (denoted PBH; n = 11) or without hypoglycemic symptoms 
(denoted Asx; n = 7), overweight subjects who had not undergone a gastric bypass 
procedure (n = 3), or severely obese patients who had not undergone a gastric bypass 
procedure (n = 4). Patients were assigned to the PBH group if they met the following 
criteria: history of RYGB surgery and documented plasma glucose levels below 55 
mg/dL with symptoms of NG. Across all groups, no patients had T2DM (as defined by 
HbA1C levels). 
 
Baseline Measurements and Mixed Meal Tolerance Test 
Patients were asked to fast overnight. Fasting blood samples were obtained upon 
arrival to our facility. These samples were denoted as baseline or “Time 0” samples (T0). 
Patients were then asked to consume a liquid mixed meal of Ensure (9 grams of protein, 
40 grams of carbohydrate, and 6 grams of fat). Additional blood samples were obtained at 
the following intervals post-mixed meal consumption: 10, 20, 30, 60, and 120 minutes, 
denoted T10, T20, T30, T60, and T120, respectively.  
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Somascan (SOMAlogic) Proteomic Analysis 
 Serum samples from baseline (fasting state; T0), as well as 30 minutes (T30) and 
120 minutes (T120) following consumption of the mixed meal were analyzed via 
SOMAscan (Somalogic, Inc.). This technology involves using modified SOMAmers to 
detect and provide relative quantification of 1,129 proteins. A SOMAmer is a high-
affinity binding aptamer with probes specific to each protein. Levels of each protein are 
quantified based on fluorescence from the SOMAmer probe. Fluorescence intensity and 
the amount of protein present are directly proportional. Protein levels are expressed in 
arbitrary units, Somamer units. The differential expression of FGF-19 between groups 
was confirmed via a sandwich enzyme-linked immunosorbent assay (ELISA) (FGF-19 
Quantikine® ELISA kit, R&D Systems), using the manufacturer's instructions.  
 
Metabolon Metabolomic Analysis 
 In parallel, the serum samples described above from T0, T30, and T120 were 
analyzed for relative metabolite levels using the Metabolon platform. This technology is 
a phenotyping tool that can be used to detect alterations in metabolite levels between 
groups. Serum metabolites are identified and quantified relatively by mass spectrometry 
using a global metabolomics platform with minimal process variability. In our samples 
307 metabolites were analyzed, and relative units can be compared between PBH and 
asymptomatic groups to determine differences in serum level of metabolites. 
 
Translational Experiment: Designing a Mouse Model of Post-Bariatric Hypoglycemia  
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Animals and Facilities 
The Institutional Animal Care and Use Committee of Joslin Diabetes Center 
approved all protocols involving mice. CD1 mice were purchased from Charles River 
Laboratories. Upon arrival at Joslin Diabetes Center, the mice were allowed an 
appropriate accommodation period of 3-5 days before beginning the experiment. Mice 
were housed in a pathogen-free facility with ad libitum access to a chow food diet and 
water. Mice were weight-matched and divided into treatment or vehicle groups at the 
commencement of each experiment.  
 
Fexaramine: Dosing Information, Glucose Tolerance Testing 
The decision to use fexaramine to activate the Bile Acid-FXR-FGF19 pathway 
was made following review of a previous experiment and communication with their 
authors19. This previous study noted that orally administered Fex resulted in GI-restricted 
Farnesoid X Receptor (FXR) activation. Activation of the BA-FXR-FGF19 pathway 
resulted in an increase in FGF15 levels, as well as its downstream targets19.  
Powdered Fex was dissolved via homogenization in a sterile corn oil vehicle due 
to the compound’s lipophilic properties.  
7-week-old male CD1 mice were administered a 100 mg/kg body weight dose of 
Fex or an equal volume of corn oil via gavage daily for 5 days. Mice were weighed daily 
to observe for significant differences in body mass between groups. On day 4, mice were 
fasted overnight for 12 hours. On the fifth day, fasted mice were dosed with Fex or 
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vehicle before undergoing IPGTT; one hour was allowed between treatment gavage and 
injection of glucose (2 gram of glucose/kg body weight of a 20% glucose solution). 
Glucose levels (mg/dL) were measured via tail vein (WaveSense Presto) over the course 
of 180 minutes. Mice were sacrificed at 180 minutes via IP injection of phenobarbital. 
Liver, small intestine, and plasma samples were collected and weighed immediately 
thereafter, and stored at -80°C. 
 
Gene Quantification 
Liver and small intestine were pulverized and homogenized using Ribozol RNA 
Extraction Reagent in order to isolate RNA according to a protocol from the 
manufacturer (Amresco, LLC). Complementary DNA was synthesized from 1 ug of RNA 
using High Capacity cDNA Reverse Transcription Kit (Bio-Rad Laboratories, Inc.); a 
protocol from the manufacturer was followed. Intestinal and liver FGF19 target genes 
were evaluated for gene expression in order to determine whether the FGF19 pathway 
was potently activated by Fex-treatment. PCR was performed using SYBR green as the 
detector. Samples were run in duplicate and relative mRNA expression was calculated 
using the Delta-Delta CT method normalized against 36B4 as a housekeeping gene. 
 
Adenine: Dosing Information, Glucose Tolerance Testing & Insulin Tolerance Testing 
Adenine hydrochloride hydrate was obtained from Sigma Aldrich; this 
compounded version of adenine was chosen in order to increase dissolution in sterile 
water.  
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Our first cohort of mice was administered a 25 mg/kg body weight dose of 
adenine (n = 3) or an equal volume of sterile water vehicle (n = 2) via IP injection for 2 
days. After being fasted overnight and receiving a second treatment dose, mice were 
administered glucose (2 g/kg) via gavage of 40% glucose solution. 30 minutes was 
allowed between IP injection of adenine or vehicle and OGTT. Glucose levels were 
measured via tail vein (Bayer Contour Next glucometer) over the course of 180 minutes. 
Upon evaluating the results of the OGTT, our group made the decision to increase the 
dose to 50 mg/kg body weight of adenine or control. A separate cohort of mice was 
administered this dose via IP injection for two days (adenine, n = 3; control, n = 3) and 
subjected to the OGTT protocol described above.  
A second cohort of mice underwent an insulin tolerance test (ITT) to evaluate 
insulin sensitivity in response to a 50 mg/kg body weight dose of adenine for 2 days. 
After a 4-hour fast mice received a second dose of treatment before injection of a 0.75 
Insulin Units/kg body weight dose of insulin. 30 minutes allowed between IP treatment 
and ITT. Glucose levels were measured via tail vein (Bayer Contour Next glucometer) 
over the course of 120 minutes. 
 
Statistical Analysis 
Statistical analyses for all studies are presented as mean ± standard error of the 
mean (SEM). Demographic data for all 4 groups were analyzed using one-way ANOVA 
with Tukey’s multiple comparisons test for continuous variables (GraphPad Prism).  For 
the purpose of comparing PBH and asymptomatic post-surgical groups, a Student’s t-test 
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was conducted to evaluate between-group differences. Pearson’s coefficient was 
calculated for regression analyses. Significance for the metabolomics data is defined as a 
false discovery rate of  ≤ 0.25. Significance for both metabolomic and proteomic analyses 
is defined as a two-tailed P value of ≤ 0.05. 
 Statistics for GTT and ITT results described above were calculated as AUC from 
baseline between treatment and control groups. An unpaired t-test was conducted to 
evaluate between-group differences and generate p-values (GraphPad Prism). 
Significance for the purpose of the mouse model experiments is defined as a two-tailed P 
value of  ≤ 0.05.  
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RESULTS 
 
Patient Characteristics 
 Our group’s primary analysis explored differences in protein and metabolite 
levels in serum samples between post-RYGB asymptomatic (Asx; n  = 7) and post-
bariatric hypoglycemic (PBH; n = 11) groups. Clinical characteristics of the Asx and 
PBH groups are defined below in Table 1. Notably, there was a difference in sex across 
groups with more women in the PBH group. There was no significant difference in BMI 
between post-RYGB groups, whether PBH or Asx; however, BMI was lower in post-
surgical patients than overweight/obese control groups.  
Average glucose values, as defined by Hemoglobin A1C (HbA1C) levels, and of 
insulin resistance, as defined by HOMA-IR, did not differ between post-surgical and/or 
overweight/obese control groups. However, fasting plasma glucose levels were 
significantly lower in post-RYGB groups (asymptomatic, 74 ± 3 mg/dL; PBH, 85 ± 4 
mg/dL) compared to the overweight and obese control groups (overweight, 97 ± 5 mg/dl; 
severely obese, 94 ± 4 mg/dl).  
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Table 1: Descriptive Statistics for the asymptomatic (Asx) and post-bariatric 
hypoglycemic (PBH) Patient Groups Assessment of these characteristics occurred 
during study visits prior to the Mixed Meal Tolerance Test. Mean ± SEM was calculated 
for each group.  
 
 
 
Asymptomatic 
 (n = 7) 
Post-Bariatric 
Hypoglycemia  
( n = 11) 
 
 Mean ±  SEM Mean ±  SEM p - value 
Male/Female 3/4 11 - 
Age (year) 50 ±  4 43 ±  3 0.17 
HbA1C (%) 5.6 ±  0.2 5.5 ±  0.1 0.34 
HOMA-IR (U) 1.2 ±  0.3 3.9 ±  2.9 0.40 
Waist (cm) 94 ±  7 92 ±  2 0.76 
Systolic BP (mmHg) 126 ±  4 116 ±  3 0.08 
Diastolic BP (mmHg) 76 ±  4 70 ±  2 0.11 
Cholesterol (mg/dL) 168 ±  11 172 ±  11 0.80 
Triglycerides (mg/dL) 80 ±  8 72 ±  13 0.64 
HDL (mg/dL) 67 ±  10 61 ±  4 0.51 
 
The PBH group trended towards higher peak glucose levels compared to the Asx 
group (PBH, 167 ± 17 mg/dL; Asx, 138 ± 7 mg/dL). The post-RYGB groups had 
significantly higher peak glucose levels than obese (123 ± 8 mg/dL) and overweight (139 
± 14 mg/dL) control groups (ANOVA, p = 0.02). The glucose nadir was also 
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significantly lower in post-RYGB groups (Asx, 71 ± 2; PBH, 77 ± 4) in comparison to 
control groups (overweight, 99 ± 4; severely obese, 95 ± 6)  (ANOVA P <0.001). 
 
Proteomic Analysis of Post-Surgical Patients with or without Symptoms of PBH  
Overall we identified twelve proteins that were upregulated in patients with PBH 
and five that were downregulated (p < 0.05) at all three time points. Of particular 
importance were proteins that were differentially expressed at 120 minutes (T120) after 
ingestion of the mixed meal, as symptoms of PBH typically occur 1 – 3 hours 
postprandially.  
Fibroblast Growth Factor 19 (FGF19) was the most abundantly differentiated 
protein in the PBH group compared to the Asx group. As can be seen in Figure 3, below, 
at T120, SOMAScan indicated FGF19 was 2.1-fold higher in patients with PBH 
compared to Asx patients (1094 ± 141 versus 428 ± 45 Somamer units, respectively; p < 
1x10-5). Levels of FGF19 were also increased, at baseline (487 ± 31 vs. 347 ± 25 
Somamer units, p < 0.01) and at 30 minutes postprandially (540 ± 48 vs. 363 ± 25 
Somamer units, p = 0.01) in the PBH group contrasted with the Asx group. To confirm 
differential abundance of the FGF19 protein between PBH and Asx patients, an ELISA 
assay was performed and found FGF19 protein in serum was 3.5-fold higher in PBH 
patients than Asx patients (360 ± 70 versus 103 ± 18 pg/mL, respectively; p < 0.05). 
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A B 
 
Figure 3: Differential abundance of FGF19 in PBH patients compared to 
asymptomatic patients (A) FGF-19 abundance in Somamer units at T0, T30, and T120 
(B) Significantly increased plasma levels of FGF19 in PBH patients at T120 were 
confirmed by ELISA. * represents p < 0.05, and ** represents p < 0.01.  
 
We next examined correlations between FGF19 and potential confounding factors 
that could account for differences between the PBH and Asx groups. The differential 
abundance of FGF19 did not correlate with age, BMI, magnitude of post-surgical weight 
loss, or postoperative duration. Interestingly, FGF19 levels were inversely correlated with 
glucose levels at T0 and T30, but positively correlated with glucose levels at T120. 
 
Metabolomic Analysis of Post-Surgical Patients with or without Symptoms of PBH  
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To identify metabolites that were upregulated or downregulated in the PBH group 
in contrast with the Asx group, we generated volcano plots. These plots can be seen 
below in Figure 4 and suggest several metabolites of interest. The most significantly 
upregulated metabolite was adenine. Adenine was increased at all time points in the PBH 
group contrasted with the Asx group. Adenine was significantly greater at baseline 
(26699 ± 1688 versus 12411 ± 1359 relative units, p < 1x10-8), at T30 (28228 ± 2593 
versus 11849 ± 1218 relative units, p < 1x10-9), and at T120 (30327 ± 2005 versus 11845 
± 1198 relative units, p < 1x10-10) in PBH patients. At T120, PBH patients had AMP 
levels that trended towards higher than Asx patients (87320 ± 25441 versus 35278 ± 8868 
relative units, p = 0.089). ADP levels were also significantly increased at T120 in PBH 
patients compared to Asx patients (229622 ± 83272 versus 69004 ± 23873 relative units, 
p = 0.01). Serum adenosine levels were not altered at any time.  
It is important to note that several other metabolites, shown below in Figure 4, 
were significantly upregulated or downregulated in the PBH group in contrast with the 
Asx group. Uridine Monophosphate (UMP) wass downregulated by ~1.5-fold at all time 
(p < 1 x 10-6). Glucuronate was upregulated by >3-fold in PBH patients at all time points 
(p < 1 x 10-5). Oxalate is significantly upregulated (>1.50-fold) at all three times points in 
the PBH group (p < 1 x 10-4); at baseline, oxalate upregulation was greatest (>2-fold). 
Isocitrate and citrate, citric acid cycle intermediates, were significantly upregulated at 
various time points in PBH patients compared to asymptomatic patients (p < 1 x 10-4). 
Isocitrate was upregulated by ~1.6-fold at T0 and T30, and citrate was upregulated by 
<1.5-fold at these time points.  
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Figure 4: Volcano plots of 
differentially abundant metabolites 
during a mixed meal tolerance test 
(MMTT)  (T0) Baseline, (T30) 30 
minutes after mixed meal,  (T120) 120 
minutes after mixed meal.  A –log (10) p-
value is graphed on the y-axis while a log 
(2)-fold change is graphed on the x-axis. 
The center of the volcano plot (x-axis = 
0) indicates no difference in relative 
expression between groups; therefore, x > 
0 indicates upregulation and x < 0 
indicates downregulation in the PBH 
group compared to the asymptomatic 
group. Statistical significance is defined 
as p < 0.05. 	
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Figure 5: Serum levels of adenine nucleotides in the fasting state as well as 30 and 
120 minutes after mixed meal Serum levels, in relative units, of adenine, adenosine, 
AMP, and ADP in the PBH group and asymptomatic group. * indicates p < 0.05; *** 
indicates p < .001. 
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Translational Experiment: Designing a Mouse Model of Post-Bariatric Hypoglycemia  
 
Fexaramine 
Fibroblast Growth Factor 19 (FGF19) was identified as a candidate protein for 
overexpression in establishing a mouse model of PBH as it showed high fold-change with 
a low p-value in our proteomic analysis detailed above. Upon further research, we found 
that FGF19, an endocrine fibroblast growth factor, plays a role in bile acid homeostasis 
and has also been linked to reduction in glucose levels and improvement of glucose 
tolerance19. Fexaramine, a bile acid analog, binds at the Farnesoid X Receptor (FXR), 
initiating a cascade that ultimately results in increased levels of FGF19 in the circulation. 
Our group wished to test the impact that dosing with Fex, and thereafter increasing 
FGF19, would have on mice. 
There were no significant differences in weights between Fex (n = 5) and control 
(n = 5) groups on days 1 – 4. As seen in Figure 6, below, there was also no significant 
difference in weight on day 5, following a 12 hour fast, between mice in treatment and 
control groups. 
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Figure 6: Body weights of fexaramine and vehicle treated mice over the duration of 
treatment Body weights (mean ± SEM) of fexaramine-treated mice did not differ 
significantly from vehicle-treated mice.  
  
On day 5, fasted mice were gavaged with treatment or control and allowed 60 
minutes before administration of glucose. Glucose levels 60 minutes after treatment or 
vehicle gavage, prior to glucose administration, trended towards lower in Fex-treated 
mice than in vehicle-treated mice. An IPGTT did not result in a significant difference in 
postprandial serum glucose levels between groups (p(AUC) = 0.41). The results from the 
IPGTT can be seen below in Figure 7. 
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Figure 7: IPGTT performed after 5 days of fexaramine or vehicle treatment 
Gavaged animals were allowed 60 minutes for treatment to traverse the proximal GI and 
activate FXR in the small intestine. (A) Fasted Fex-treated animals exhibited lower 
glucose levels at 60 minutes post-gavage; however, this difference between groups did 
not reach statistical significance (p = 0.12). This difference toward lowered glucose levels 
in Fex-treated mice was not maintained after the administration of glucose. (B) IPGTT 
differences between groups were not statistically significant (p(AUC) = 0.41)).  
 
 In order to determine whether treatment with fexaramine resulted in FGF19 
activation, gene expression of FXR, FGF15, and its downstream targets were evaluated 
via PCR.  Fexaramine binding at FXR should increase FGF15 in the ileum. DIET1 
expression in the ileum enhances FGF15/19 transport and therefore plays a role in the 
FXR-BA-FGF15/19 pathway. FGF15/19 systemic binding requires B-Klotho (KLB) as a 
cofactor. FGF15 downstream systemic effects include inducing hepatic expression of 
Small Heterometric Protein (SHP), which suppresses Cyp7a1 expression24,26. FGF15 
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binds to FGFR4 in the liver, inhibiting bile acid production and release from the 
gallbladder24. 
 
A B 
 
Figure 8: Gene expression of FGF19 target genes (A) Ileal gene expression and (B) 
hepatic gene expression. Fold-Change, normalized to 36B4, compares log change in 
relative gene expression between Fex-treated and control groups. Error bars are expressed 
as SEM. 
 
 Figure 8 above shows normalized gene expression as measured by PCR. There 
were no significant differences in gene expression between groups. Expression of DIET1, 
FXR, SHP, and FGF15 in the ileum as well as KLB, FGFR4, and CYP7a1 in the liver 
was not changed. 
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Adenine 
After reviewing the volcano plots generated from the metabolomics data (Figure 
4, above), our group identified adenine as a metabolite of interest. Adenine was robustly 
higher at all time points during the MMTT (T0, T30, and T120) in the PBH group than in 
the Asx group. We were particularly intrigued by this data given adenine nucleotides’ 
widely known role in energy metabolism.   
Adenine was initially administered at a dose of 25 mg/kg body weight for 2 days. 
This dose did not significantly impact glucose tolerance in response to OGTT between 
groups. Upon reviewing the results of the preliminary dose, the decision was made to 
increase the dose of adenine while maintaining the duration of treatment. An increased 
dose of 50 mg/kg body weight of adenine or sterile water vehicle did not significantly 
impact glucose tolerance between groups. As can be seen in Figure 9, below, there were 
no significant differences between groups over the 180-minute OGTT and AUC from 
baseline between groups did not differ significantly.  
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Figure 9: OGTT results following 2 days of 50 mg/kg body weight adenine 
treatment Glucose levels over the course of OGTT of each animal in adenine (blue; n = 
3) and control (red; n = 3) groups. The insert shows calculated area under the curve 
(AUC) over baseline, which was not statistically different between groups (p = 0.36).   
 
Treating mice with 50 mg/body weight adenine or vehicle for 2 days did not result 
in a significant difference in insulin sensitivity (in response to ITT) between adenine and 
control-treated groups, as can be seen in Figure 10 below. 
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Figure 10: ITT results following 2 days of 50 mg/kg body weight adenine treatment 
Glucose levels over the course of 120 minutes in response administration of insulin. The 
insert shows calculated AUC over baseline between groups was not significantly 
different (p = 0.47).  
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DISCUSSION 
 
Results of Proteomics & Metabolomics Data 
 The results of the proteomics and metabolomics analyses indicate several 
candidate molecules that may be altered as either a cause or a result of the PBH state.  
The target proteins and metabolites chosen for the animal experiments were selected 
because they were either upregulated or downregulated by a high-fold change with a low 
p-value indicating statistical significance.  
 An important consideration, particularly with regards to the metabolomics data, is 
that serum levels of metabolites and proteins can change rapidly over the course of a 
meal. However, the volcano plots in Figure 4 compare PBH patients with asymptomatic 
patients at equal points throughout a MMTT, and therefore, we consider the differences 
at each time point (including T30 and T120) to be relevant to differences in the patients’ 
conditions. It is important to analyze each of the significantly upregulated or 
downregulated metabolites both individually and with regard to their interconnectedness 
in metabolic pathways. Notably, the significant upregulation of adenine nucleotides and 
downregulation of uridine nucleotides at all time points indicates alterations in nucleotide 
metabolism. 
 
Fibroblast Growth Factor 19 (FGF19) 
Fibroblast Growth Factor 19 (FGF19) is an ileal-secreted hormone that is 
involved in the bile acid homeostasis. Bile acids are released into the small intestine 
postprandially and bind to the TGR5, a G-Protein Coupled Receptor (GPCR) on the ileal 
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lumen20. After being transported into the enterocyte, the bile acid will interact with the 
bile acid nuclear receptor Farnesoid X Receptor (FXR). The interaction between bile 
acids and FXR upregulates the transcription of FGF1921,22.  
 FGF19 and its murine ortholog, Fibroblast Growth Factor 15 (FGF15), are 
endocrine fibroblast growth factors (FGFs). They are able to travel in the blood and have 
systemic effects due to decreased affinity for heparin sulfate, unlike autocrine or 
paracrine FGFs.  FGF19 has several different receptors including FGFR4 and FGFR1. 
FGFR4 is abundant in the liver, but is found in other tissues including the pancreas and 
brown adipose tissue. FGFR4 regulates bile acid secretion and synthesis by 
downregulating the transcription of Cyp7a1, the rate-limiting enzyme in bile acid 
synthesis, by inducing the expression of SHP26. FGFR4 has also been linked to increased 
gallbladder filling and decreased secretion of bile acids into the small intestine19. 
Although, it is undetermined whether FGF19 binding increases or decreases circulating 
lipids due to binding at different receptors24.  
Via a non-insulin dependent method, FGF19 modulates glucose metabolism, 
likely through FGFR1 and/or FGFR4 receptors. FGF19 administration reduces glucose 
levels and improves glucose tolerance in high fat diet-fed (HFD) mice as compared with 
vehicle-treated controls. These glycemic improvements occur in parallel with reduced 
weight gain and increased metabolic rate 19,23. Transgenic mice overexpressing FGF19 
had lower serum glucose levels and increased glucose tolerance despite having decreased 
insulin levels26. Additionally, elevating FGF19 levels by either direct injection or 
transgenic overexpression in mice can reverse obesity and improve insulin resistance and 
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hyperglycemia25,26. Collectively, these findings reveal that FGF-19 improves glucose 
homeostasis via several mechanisms, particularly via non-insulin dependent glucose 
disposal.  
 
 
Figure 11: Possible mechanisms by which FGF19 modulates glucose and can 
contribute to PBH The FGF19-induced glucose lowering mechanism has not been fully 
elucidated. Bile acid (green rectangles) binding at FXR in enterocytes increases 
transcription of FGF15/19, which regulates bile acid synthesis. FGF19 binds at FGFR4 
(blue receptor) and FGFR1 (orange receptor) in various tissues to have systemic effects 
including improved glucose tolerance and decreased serum glucose levels. 
 
 From our literature review, which is summarized in Figure 11 above, FGF19 
administration results in significant glycemic improvements. Thus, the obvious treatment 
	33	
to increase serum FGF19 levels in mice would be injection of the recombinant protein. 
However, recombinant FGF19 is not readily available for purchase; special ordering 
FGF19 is both expensive and requires a several week lead-time. As such, we decided to 
initially pursue a different experimental model for the purpose of elevating serum FGF19 
levels. 
 A previous study that administered a bile acid analog, fexaramine, and reported 
Gastrointestinal (GI)-specific (deemed “gut-restricted”) activation of the Bile Acid–
FXR–FGF19 pathway19. Our laboratory wanted to reproduce this experiment as a 
potential model of PBH due to the glucose lowering effects of FXR activation. The Fang, 
et al. study noted that Fex’s glycemic lowering effects, as well as its activation of the BA-
FXR-FGF15 pathway, were prominent after 3 weeks of treatment19. However, some 
significant differences in gene expression within the BA-FXR-FGF15 pathway were 
reported after just 3 days of treatment with Fex. Changes in gene expression were more 
significant in the small intestine than in the liver at 3 days. Our protocol involved gut-
restricted dosing (via gavage) of Fex for a total of 5-days. However, we noted a less 
potent alteration in the gene expression BA-FXR-FGF19 target genes and downstream 
targets than the Fang, et al. study. Our results may have differed from the Fang, et al. 
study due to our small sample size (n = 5 per group) and reduced duration (5-days) of 
treatment; both of which limit the power of our study.  
 Our PCR results appear to indicate some level of activation of the BA-FXR-
FGF15 axis. However, when contrasted with the Fang, et al. study’s gene expression 
results (showing > 2-fold increase of FGF15 (p < 0.01), a 1.5-fold decrease in Cyp7a1 
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(p< 0.01), and a >2.5-fold increase in SHP (p < 0.05) after 3 days of fex-treatment), it 
does not appear that our experiment achieved robust activation of the BA-FXR-FGF15 
pathway19. We observed substantial variability between animals – together with our small 
sample size - we likely did not have adequate power to prove FXR target genes were 
differentially expressed between groups. If elevated FGF19 contributes to hypoglycemic 
events in PBH patients, unambiguously elevated FGF15/19 levels are necessary to 
establish a murine model of PBH. We do not feel that acute treatment with Fex will 
reliably achieve elevated levels of FGF15/19 necessary to result in hypoglycemia. The 
PCR gene expression results confirmed that we were unable to reject the null hypothesis.  
 
Adenine 
Adenine nucleotides, AMP, ADP, and ATP, have historically been linked to 
intracellular energy transfer. Hydrolysis of the high-energy phosphoanhydride bonds in 
these molecules can be coupled to less favorable endergonic reactions. These adenine 
nucleotides are formed from a smaller nucleoside adenosine, a nucleobase attached to a 
ribose sugar. Adenosine can be stripped of its ribose to form the simple nucleobase 
adenine. Recent research aims to expand upon the current knowledge of adenine 
nucleotides’ physiological function and role in metabolism, including evaluating the 
individual roles of adenosine and adenine in metabolism33.  
Purine metabolism weaves a complex, interconnected web of catabolism and 
anabolism that involves both endogenous de novo syntheses as well as salvage pathways. 
The enzyme purine nucleoside phosphorylase cleaves the ribose from adenosine 
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converting the molecule to adenine in an irreversible reaction. However, physiological 
levels of adenine are closely regulated. To keep levels within a narrow physiological 
range, adenine is converted to AMP via the purine salvage pathway enzyme adenine 
phosphoribosyl transferase (APRT).  
Endogenous adenosine is generated intracellularly as a breakdown product of 
AMP via the enzyme 5’nucleotidase. Intracellular adenosine is released from cells as a 
vasoactive metabolite, which acts in a paracrine or autocrine manner to maintain energy 
balance within the cells29. Adenosine release has also been implicated as a physiological 
response to cell injury and inflammation30.  
Adenosine may also be generated extracellularly from AMP via the activity of 
ecto-5’-nucleotidase31. Extracellular adenosine has a short half-life32. In plasma, 
adenosine is quickly being broken down (half-life ~ 10s) or acts on the adenosine 
receptors, A1, A2A, A2B and A332,33. These GPCRs are widely expressed throughout the 
body and have been implicated in pathophysiology, such as anginal pain, as well as 
therapeutically in several diseases, including as an antiarrhythmic drug. Adenosine 
receptors are either adenylyl cyclase stimulating (both of the A2 adenosine receptors) or 
adenylyl cyclase inhibiting (A1 and A3)34.  
Although much remains to be elucidated regarding each of these adenosine 
receptors, existing research has begun to expand upon adenosine’s physiological role and 
the role of adenosine receptor signaling in systemic processes.  
A1 receptors are the most prevalent of the adenosine receptor subtypes35. The A1 
receptor’s actions are associated with G-protein inhibitory (Gi) actions, including 
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decreasing cyclic AMP (cAMP) via reduction of adenylyl cyclase activity, activating 
potassium channels, inhibiting calcium channels, and increasing vascular tone34. 
Physiologically, A1 receptors have been linked to decreased renal blood flow and 
inhibition of the renin-angiotension-aldosterone system36, inhibition of neurotransmitter 
release37, analgesia37, bone resorption38, as well as decreased heart rate39.  
Of interest to our group is the impact adenosine receptors appear to have on 
metabolism. These impacts are detailed below in Figure 12. In diabetic rats, A2BAR 
mRNA was decreased; however, A3 and A2A receptor mRNA was increased. Treatment 
with insulin resulted in return of adenosine receptor expression to normal within days. 
This suggests an interplay between insulin secretion and most of the subtypes of 
adenosine receptor expression47.  
A1 receptors are present in adipose tissue and inhibit lipolysis via the reduction of 
cAMP levels in adipocytes40. The A1 receptor antagonist DPCPX can increase lipolysis 
and increase levels of cAMP in adipocytes41. A1 receptor-specific agonists also increase 
circulating leptin by increasing its secretion from adipocytes42. Insulin-influenced glucose 
uptake is not inhibited by the absence of adenosine; rather adenosine’s mechanism acts 
synergistically with the insulin receptor to increase glucose uptake43. A study found that  
A1 receptor knockout mice exhibited elevated and sustained insulin and glucagon 
responses. However, in contrast with previous studies, this study did not find a difference 
in glucose uptake in muscles between A1 receptor knockouts and wild-type groups43. This 
paper implies that A1AR acts primarily at islets. Another paper confirms that high levels 
of adenosine potentiated glucose-induced insulin secretion, thus resulting in higher levels 
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of serum insulin44. These results coupled with adenosine’s impact on glucose uptake 
imply that, though insulin secretion and activity do not rely on adenosine levels, higher 
levels of adenosine may improve glucose tolerance and insulin sensitivity. 
Additional research suggests other adenosine receptors may influence insulin 
resistance and glucose metabolism. Mice treated with a nonselective adenosine antagonist 
(5’-N-ethylcarboxamidoadenosine) exhibit increased fasting glucose levels as well as 
decreased glucose clearance. If A2B receptors are deleted, these antagonistic effects are 
inhibited. Deleting either A2A receptors or A1 receptors does not attenuate the effects of 
the adenosine antagonist46. These diabetic mice had dramatically increased A2B receptor 
mRNA expression in endothelial cells and macrophages46. Inhibitory effects on hepatic 
glucose production are greater using an A2B selective antagonist than an antagonist 
selective to any other adenosine receptor; this suggests that the A2B receptor has the 
greatest impact on hepatic glucose production47.  
A previous study found that altered gene methylation following bariatric surgery 
resulted in a 10% decrease in methylation of the ADK gene, which codes for adenosine 
kinase. This gene is a known regulator of adenosine and adenine levels53. Adenosine 
kinase catalyzes the transfer of a phosphate from ATP to adenosine, and as such, 
regulates both extracellular and intracellular levels of adenosine and other adenine 
nucleotides. This change in DNA methylation may be further augmented in PBH patients. 
Although, it remains uncertain whether altered adenine and/or adenosine expression is a 
cause or an effect of the PBH symptoms.  
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 Figure 12: Possible glucose modulating mechanisms of adenosine receptor binding 
Adenosine (blue oval) binding appears to work synergistically with the insulin receptor 
(black lines) to increase glucose uptake at muscle cells. Adenosine binding at adenosine 
receptors is linked to systemic improvements in glucose uptake as well as a decreased 
fasting glucose. Debate remains on which adenosine receptor is responsible for these 
glycemic impacts. A key question in our study is whether adenine, itself, is acting at 
adenosine receptors or if high levels of adenosine, which are rapidly degraded in the 
serum, are responsible for these effects. 
 
It was previously noted that inosine could act as a partial agonist at adenosine 
receptors A1 and A3 48. Considering adenine resembles adenosine structurally, with the 
exception of the attachment of a ribose sugar, it is possible that adenine may have affinity 
for one, if not all, of the adenosine receptors.  In fact, an adenine-binding site has been 
identified at the A1AR receptor49. As the results of our experiment failed to yield 
	39	
significantly different responses to OGTT and ITT, we have not yet concluded whether 
high levels of adenine are a cause or an effect of the PBH condition.  
 Oral administration of adenine in mice has been used to establish a model of 
chronic renal failure and continues to be used to study systemic effects associated with 
chronic renal failure50,51. In rats, chronic renal failure can be modeled via IP injection of 
adenine52. Despite numerous studies being performed administering exogenous adenine 
to rodents, information regarding adenine’s glucose modulating effects has not been 
expanded upon. The studies we reviewed in developing our protocol indicated that 
chronic treatment with adenine results in kidney disease50-52. Care was taken to assure we 
selected a dose that would not increase mortality nor drastically alter physiological 
function of our mice. This may be a limitation of our study, as we did not assay adenine 
levels, thus we cannot be sure adenine levels were suitably elevated. 
Glucose tolerance testing of our adenine cohorts did not yield statistically 
significant results between adenine and control groups. As stated above, there is some 
uncertainty in our experimental design as to whether adenine levels were adequately 
increased in mice to elicit glycemic responses.  
	40	
CONCLUSION 
 
The results of the proteomic and metabolomics analyses that are detailed above 
suggest several candidate molecules related to the PBH condition. Though these results 
are strictly correlational and cannot prove causality, they do provide insight into various 
proteins and metabolites that can be experimentally altered individually and in 
combination to establish a murine model of PBH. Further data from human studies may 
reveal additional factors that are altered in the PBH condition or cast a light on the factors 
described above that are universally upregulated or downregulated in PBH patients. A 
future study could improve upon the fidelity of our study by balancing the number of 
patients of each gender, thus ruling out gender as a confounding variable.   
The animal studies, detailed above, indicate that the etiology and pathogenesis of 
PBH are complex and likely involve multiple factors. In our initial studies, we attempted 
to experimentally modify a single factor in order to elicit hypoglycemia and, therefore, 
minimize confounding variables. However, the PBH condition likely involves several 
pathways; as such, altering just one variable may not affect physiology enough to induce 
hypoglycemia.  
Our animal studies involving FGF19 failed to result in postprandial 
hypoglycemia, and as such are not reliable models of PBH. Moving forward with these 
studies, our group may decide to administer recombinant FGF19 or even a FGF19 
adenovirus to ensure serum levels of FGF19, the major glycemic modulator of the BA-
FXR-FGF19 pathway, are chronically increased. We wish to rule out the differential 
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hypothesis that FGF19 expression is increased by hypoglycemia, by collecting and 
analyzing serum samples of hypoglycemic animals for FGF19 expression.  
 Our group plans to continue to explore the etiology of PBH using rodent models 
by collaborating with other laboratories exploring the post-RYGB metabolic condition. In 
specific, we will be collaborating with laboratory that has performed RYGB on Long 
Evans and Goto-Kakizaki rats. These post-RYGB rats have been evaluated for the impact 
intestinal glucose metabolism reprogramming has on improved metabolic conditions and 
remission of T2DM following bariatric surgery54. 
  Although, we failed to reject the null hypothesis in our murine adenine 
experiment, this study can be refined and expanded upon. Our group plans to obtain a 
non-selective adenosine agonist and use this agonist as a positive control in future 
experiments33. Another element of ambiguity in our previous experiments was our 
uncertainty as to whether adenine levels were elevated. We plan to address this in future 
studies by assaying for adenine via mass spectrometry. 
  Although, our animal experiments failed to yield significant results, they have 
ruled out potential independent mechanisms and suggest that we should proceed by 
altering candidate molecules in combination as opposed to singularly. As such, we plan 
to proceed by increasing expression of the afore-discussed factors in combination (for 
example, FGF19 or adenine + GLP-1 agonist). We will continue to use future post-
RYGB metabolomics and proteomic results to refine our experiments until we have 
developed a murine model of PBH. 
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